Association between the interleukin-13 gene and development of chronic obstructive pulmonary disease in southern Chinese Han population: A case-control study

Chinese Medical Journal

Volumn 126, Issue 23, 2013, Pages 4403-4408

  Gong, Yi ^a   Shi, Guo Chao ^b   Wan, Huan Ying ^b   Yang, Kun ^b   Pan, Chun Ming ^b   Cheng, Qi Jian ^b   Dai, Ran Ran ^b   Li, Qing Yun ^b   Li, Min ^b   Zhou, Min ^b   Guo, Yi ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Case control study; Chronic obstructive pulmonary disease; Gene polymorphism; Interleukin 13

Indexed keywords

INTERLEUKIN 13;

ADULT; ALLELE; ARTICLE; CHINESE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; INTERLEUKIN 13 GENE; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INTERLEUKIN-13; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84888255850     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130225     Document Type: Article

References (46)

1. Jorgen V, Calverley P, Agusti AG, Committeeobot GS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. 2010. (Accessed March 2012 at http://www. goldcopd. org).
2. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282: 2258-2261.
3. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev 2004; 202: 175-190.
4. Whittaker L, Niu N, Temman UA, Stoddard A, Flavell RA, Ray A, et al. Interleukin-13 mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and interleukin-9. Am J Respir Cell Mol Biol 2002; 27: 593-602.
5. Sluiter H, Koeter G, De Monchy J, Postma D, De Vries K, Orie N. The Dutch hypothesis (chronic non-specific lung disease) re-visited. Eur Respir J 1991; 4: 479-489.
6. Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, Riese RJ, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase-and cathepsin-dependent emphysema. J Clin Invest 2000; 106: 1081-1093.
7. Miotto D, Ruggieri M, Boschetto P, Cavallesco G, Papi A, Bononi I, et al. Interleukin-13 and-4 expression in the central airways of smokers with chronic bronchitis. Eur Respir J 2003; 22: 602-608.
8. Saha S, Mistry V, Siva R, Parker D, May R, Bradding P, et al. Induced sputum and bronchial mucosal expression of interleukin-13 is not increased in chronic obstructive pulmonary disease. Allergy 2008; 63: 1239-1243.
9. Ezzeldin N, Shalaby A, Saad-Hussein A, Ezzeldin H, El Lebedy D, Farouk H, et al. Association of TNF-α-308G/A, SP-B 1580 C/T, IL-13-1055 C/T gene polymorphisms and latent adenoviral infection with chronic obstructive pulmonary disease in an Egyptian population. Arch Med Sci 2012; 8: 286-295.
10. Gong Y, Fan L, Wan H, Shi Y, Shi G, Feng Y, et al. Lack of association between the TGF-β1 gene and development of COPD in Asians: a case-control study and meta-analysis. Lung 2011; 189: 1-11.
11. Rabe K, Hurd S, Anzueto A, Barnes P, Buist S, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
12. Song HD, Liang J, Shi JY, Zhao SX, Liu Z, Zhao JJ, et al. Functional SNPs in the SCGB3A2 promoter are associated with susceptibility to Graves' disease. Hum Mol Genet 2009; 18: 1156-1170.
13. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229.
14. Lee S, Kim M, Kang H, Yoo S, Choi Y, Lee W, et al. Polymorphisms in matrix metalloproteinase-1,-9 and-12 genes and the risk of chronic obstructive pulmonary disease in a Korean population. Respiration 2010; 80: 133-138.
15. Zhou M, Huang SG, Wan HY, Li B, Deng WW, Li M. Genetic polymorphism in matrix metalloproteinase-9 and the susceptibility to chronic obstructive pulmonary disease in Han population of south China. Chin Med J 2004; 117: 1481-1484.
16. Zidzik J, Slaba E, Joppa P, Kluchova Z, Dorkova Z, Skyba P, et al. Glutathione S-transferase and microsomal epoxide hydrolase gene polymorphisms and risk of chronic obstructive pulmonary disease in Slovak population. Croat Med J 2008; 49: 182-191.
17. Lakhdar R, Denden S, Knani J, Leban N, Daimi H, Hassine M. Relationship between glutathione S-transferase P1 polymorphisms and chronic obstructive pulmonary disease in a Tunisian population. Genet Mol Res 2010; 9: 897-907.
18. Yanbaeva DG, Wouters EF, Dentener MA, Spruit MA, Reynaert NL. Association of glutathione-S-transferase omega haplotypes with susceptibility to chronic obstructive pulmonary disease. Free Radic Res 2009; 43: 738-743.
19. Schwabe K, Vacca G, Duck R, Gillissen A. Glucocorticoid receptor gene polymorphisms and potential association to chronic obstructive pulmonary disease susceptibility and severity. Eur J Med Res 2009; 14 Suppl 4: 210-215.
20. Hegab AE, Sakamoto T, Uchida Y, Nomura A, Ishii Y, Morishima Y, et al. Promoter activity of human tissue inhibitor of metalloproteinase 2 gene with novel single nucleotide polymorphisms. Respirology 2005; 10: 27-30.
21. Hirano K, Sakamoto T, Uchida Y, Morishima Y, Masuyama K, Ishii Y, et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 2001; 18: 748-752.
22. Yanbaeva DG, Dentener MA, Spruit MA, Houwing-Duistermaat JJ, Kotz D, Passos VL, et al. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study. BMC Med Genet 2009; 10: 23: 1-11.
23. Dejan T, Mirkovska SJ, Aleksandar P, Ana S, Efinska MO, Emilija S, et al. Association of cytokine gene polymorphisms with chronic obstructive pulmonary disease in Macedonians. Iran J Allergy Asthma Immunol 2009; 8: 31-42.
24. Beghe B, Hall I, Parker S, Moffatt M, Wardlaw A, Connolly M, et al. Polymorphisms in IL13 pathway genes in asthma and chronic obstructive pulmonary disease. Allergy 2010; 65: 474-481.
25. Jiang L, He B, Zhao MW, Ning LD, Li XY, Yao WZ. Association of gene polymorphisms of tumour necrosis factor-α and interleukin-13 with chronic obstructive pulmonary disease in Han nationality in Beijing. Chin Med J 2005; 118: 541-547.
26. van der Pouw KT, Küükaycan M, Bakker A, Baggen J, Van Der Zee J, Dentener M, et al. Chronic obstructive pulmonary disease is associated with the-1055 IL-13 promoter polymorphism. Genes Immun 2002; 3: 436-439.
27. Howard TD, Koppelman GH, Xu J, Zheng SL, Postma DS, Meyers DA, et al. Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet 2002; 70: 230-236.
28. Howard TD, Whittaker PA, Zaiman AL, Koppelman GH, Xu J, Hanley MT, et al. Identification and association of polymorphisms in the interleukin 13 gene with asthma and atopy in a Dutch population [A]. Genetics of asthma and atopy[C]. The Netherlands: Groningen; 2001: 183-200.
29. Kabesch M, Schedel M, Carr D, Woitsch B, Fritzsch C, Weiland SK, et al. IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. J Allergy Clin Immunol 2006; 117: 269-274.
30. Howard TD, Whittaker PA, Zaiman AL, Koppelman GH, Xu J, Hanley MT, et al. Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population. Am J Respir Cell Mol Biol 2001; 25: 377-384.
31. Hegab AE, Sakamoto T, Saitoh W, Massoud HH, Massoud HM, Hassanein KM, et al. Polymorphisms of IL4, IL13, and ADRB2 genes in COPD. Chest 2004; 126: 1832-1839.
32. He B, Zhao M, Ning L, Jiang L, Yao W. The study of interleukin-13 gene promoter polymorphism in patients with chronic obstructive pulmonary disease. Chin J Tuberc Res Dis (Chin) 2004; 27: 529-532.
33. Chu J, Huang W, Kuang S, Wang J, Xu J, Chu Z, et al. Genetic relationship of populations in China. Proc Natl Acad Sci U S A 1998; 95: 11763-11768.
34. Weng Z, Yuan Y, Du R. Analysis of the genetic structure of human populations in China. Acta Anthropol Sin 1989; 8: 261-268.
35. Ke Y, Su B, Song X, Lu D, Chen L, Li H, et al. African origin of modern humans in East Asia: a tale of 12 000 Y chromosomes. Science 2001; 292: 1151-1153.
36. van der Pouw KT, Van Veen A, Boeije L, Van Tuyl S, De Groot E, Stapel S, et al. An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun 1999; 1: 61-65.
37. Cameron L, Webster RB, Strempel JM, Kiesler P, Kabesch M, Ramachandran H, et al. Th2 cell-selective enhancement of human IL13 transcription by IL13-1112C> T, a polymorphism associated with allergic inflammation. J Immunol 2006; 177: 8633-8642.
38. Vladich FD, Brazille SM, Stern D, Peck ML, Ghittoni R, Vercelli D. IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation. J Clin Invest 2005; 115: 747-754.
39. Elias JA, Lee CG, Zheng T, Ma B, Homer RJ, Zhu Z. New insights into the pathogenesis of asthma. J Clin Invest 2003; 111: 291-298.
40. Wills-Karp M, Chiaramonte M. Interleukin-13 in asthma. Curr Opin Pulm Med 2003; 9: 21-27.
41. Bartalesi B, Cavarra E, Fineschi S, Lucattelli M, Lunghi B, Martorana P, et al. Different lung responses to cigarette smoke in two strains of mice sensitive to oxidants. Eur Respir J 2005; 25: 15-22.
42. Belperio JA, Dy M, Burdick MD, Xue YY, Li K, Elias JA, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2002; 27: 419-427.
43. Lukacs NW, Tekkanat KK, Berlin A, Hogaboam CM, Miller A, Evanoff H, et al. Respiratory syncytial virus predisposes mice to augmented allergic airway responses via IL-13-mediated mechanisms. J Immunol 2001; 167: 1060-1065.
44. Homer RJ, Zheng T, Chupp G, He S, Zhu Z, Chen Q, et al. Pulmonary type II cell hypertrophy and pulmonary lipoproteinosis are features of chronic IL-13 exposure. Am J Physiol Lung Cell Mol Physiol 2002; 283: L52-L59.
45. Ito Y, Mason RJ. The effect of interleukin-13 (IL-13) and interferon-γ (IFN-γ) on expression of surfactant proteins in adult human alveolar type II cells in vitro. Respir Res 2010; 11: 157.
46. Vargaftig BB, Singer M. Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine interleukin-13. Am J Respir Cell Mol Biol 2003; 28: 410-419.